Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials
Alimentary Pharmacology & Therapeutics · 17.11.2026
DOI: 10.1111/apt.71107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 17.11.2026. Verfasst von Anahita Rabiee und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Yale University, New Haven, Connecticut, USA. Die Arbeit nennt 79 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Decompensated cirrhosis has traditionally been considered irreversible. However, evidence shows that patients who achieve control or cure of the underlying liver disease aetiology can experience substantial clinical improvement, termed ‘cirrhosis recompensation’, formally defined by Baveno VII and further modified during Baveno VIII. This review synthesizes current knowledge on the pathophysiology, predictors, aetiology‐specific outcomes, clinical implications and trial design considerations relevant to recompensation.
Methods
We conducted a narrative review synthesizing data across six domains: pathophysiology of decompensation and recompensation; predictors of recompensation; prevalence and prognostic impact by aetiology; unresolved controversies in definition; clinical implications, including medication de‐escalation, transplant delisting and hepatocellular carcinoma (HCC) surveillance; and methodological considerations for clinical trial design.
Results
Recompensation occurs in an estimated 35% of patients with decompensated cirrhosis and is associated with reduced liver‐related mortality, though rates vary substantially by aetiology. Proposed mechanisms include reduced portal pressure, restored gut barrier integrity and possible fibrosis regression. Despite improved outcomes, HCC risk and, in some patients, portal hypertension persist, warranting ongoing surveillance. Some aspects of the definition remain unresolved, including uncertain applicability to etiologies lacking a clear curative therapy. As a trial endpoint, recompensation is clinically meaningful and sufficiently prevalent, though it requires appropriate handling of competing risks and consideration of multi‐state modelling and outcome‐ranking approaches.
Conclusions
Cirrhosis recompensation represents a paradigm shift in the understanding and management of decompensated liver disease. Future work should focus on validating recompensation criteria across diverse etiologies, clarifying underlying mechanisms and durability and establishing standardized methodological frameworks for incorporating recompensation into clinical trial design.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Yale University, New Haven, Connecticut, USA.
- VA-CT Healthcare System, West Haven, Connecticut, USA.
- Department of Medicine, University of Padova, Padova, Italy.
- Unit of Internal Medicine and Hepatology, University Hospital of Padova, Padova, Italy.
- Center for Liver Disease and Transplantation, Columbia University, New York, New York, USA.
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California, San Diego, La Jolla, California, USA.
ORCID-Profile: Anahita Rabiee, Salvatore Piano, Rohit Loomba
Zitieren
APA
Rabiee, A., Piano, S., Verna, E. C., & Loomba, R. (2026). Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71107
Vancouver
Rabiee A, Piano S, Verna EC, Loomba R. Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71107
BibTeX
@article{Rabiee2026,
author = {Rabiee, Anahita and Piano, Salvatore and Verna, Elizabeth C and Loomba, Rohit},
title = {Review Article: Cirrhosis Recompensation‐ Definition, Natural History, Clinical Implications and Considerations for Clinical Trials},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.71107}
}
EUVIMED